# The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients

> **NCT02327039** · PHASE4 · COMPLETED · sponsor: **University of Padova** · enrollment: 33 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Dapagliflozin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02327039
- **Lead sponsor:** University of Padova
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 33 (ACTUAL)
- **Last updated:** 2019-08-02

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02327039

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02327039, "The Effects of Dapagliflozin on HDL Particles Subtypes and Reverse Cholesterol Transport in Type 2 Diabetic Patients". Retrieved via AI Analytics 2026-09-24 from https://api.ai-analytics.org/clinical/NCT02327039. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*